1. Home
  2. MLYS vs RES Comparison

MLYS vs RES Comparison

Compare MLYS & RES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • RES
  • Stock Information
  • Founded
  • MLYS 2019
  • RES 1984
  • Country
  • MLYS United States
  • RES United States
  • Employees
  • MLYS N/A
  • RES N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • RES Oilfield Services/Equipment
  • Sector
  • MLYS Health Care
  • RES Energy
  • Exchange
  • MLYS Nasdaq
  • RES Nasdaq
  • Market Cap
  • MLYS 890.6M
  • RES 977.3M
  • IPO Year
  • MLYS 2023
  • RES N/A
  • Fundamental
  • Price
  • MLYS $14.89
  • RES $4.77
  • Analyst Decision
  • MLYS Strong Buy
  • RES Hold
  • Analyst Count
  • MLYS 4
  • RES 4
  • Target Price
  • MLYS $27.00
  • RES $4.69
  • AVG Volume (30 Days)
  • MLYS 881.7K
  • RES 1.9M
  • Earning Date
  • MLYS 08-12-2025
  • RES 07-24-2025
  • Dividend Yield
  • MLYS N/A
  • RES 3.36%
  • EPS Growth
  • MLYS N/A
  • RES N/A
  • EPS
  • MLYS N/A
  • RES 0.25
  • Revenue
  • MLYS N/A
  • RES $1,426,699,000.00
  • Revenue This Year
  • MLYS N/A
  • RES $12.58
  • Revenue Next Year
  • MLYS N/A
  • RES $6.53
  • P/E Ratio
  • MLYS N/A
  • RES $19.05
  • Revenue Growth
  • MLYS N/A
  • RES N/A
  • 52 Week Low
  • MLYS $8.24
  • RES $4.10
  • 52 Week High
  • MLYS $18.38
  • RES $7.22
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 55.68
  • RES 55.84
  • Support Level
  • MLYS $14.26
  • RES $4.34
  • Resistance Level
  • MLYS $15.55
  • RES $4.50
  • Average True Range (ATR)
  • MLYS 0.85
  • RES 0.16
  • MACD
  • MLYS 0.18
  • RES 0.02
  • Stochastic Oscillator
  • MLYS 77.53
  • RES 94.68

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About RES RPC Inc.

RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. The company's operating segment includes Technical Services and Support Services. It generates maximum revenue from the Technical Services segment. Technical Services segment nclude RPC's oil and gas services that utilize people and equipment to perform value-added completion, production and maintenance services directly to a customer's well. Support Services segment consists of drill pipe and related tools, pipe handling, pipe inspection and storage services, and oilfield training and consulting services.

Share on Social Networks: